MabCure forges $10M equity deal; Labopharm shares rise on drug approval;

 @FierceBiotech: Pfizer, Theraclone ink $632 R&D deal for cancer, infectious disease. News | Follow @FierceBiotech

> MabCure has inked a $10 million equity deal with Centurion Private Equity, an institutional investor managed by Roswell Capital Partners. MabCure intends to use the funding facility to fund clinical trials and ongoing research and development. MabCure release

> Shares of Labopharm shot up after Canadian regulators approved its once-daily formulation of the antidepressant trazodone. Report

> The FDA has set September 1 as its deadline for a decision on Adventrx's application for Exelbine, a new formulation of Navelbine. Story

> Perrigo has struck a deal to buy the assets of Paddock Labs for $540 million. Report

> Cognition Therapeutics, a drug discovery company developing treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing. Cognition release

And Finally... Researchers in Taiwan have been exploring the use of a Chinese herbal remedy as a replacement for surgery to correct cataracts. Story